LONDON, Feb. 1 /PRNewswire/ -- Chiltern, the global contract research
organization, announced today that it has acquired the business of Drug
Development Solutions ('DDS'), a leading Phase 1 unit located at Ninewells
Hospital and Medical School, Dundee, Scotland. Ninewells is one of the
United Kingdom's major teaching hospitals. The purchase of DDS supplements
Chiltern's Clinical Research Unit in Slough near London.
DDS was founded in 1982 and has completed more than 700 Phase I trials.
The unit offers 42 high intensity care beds with the ability to expand
these to 60 and has been ISO 9001 certified since 1997. The unit is one of
a small number in the United Kingdom that is located within a major
hospital that can provide emergency medical services if required. This will
allow the unit to attain the higher level of voluntary accreditation
available for Phase 1 units from the UK regulator, the MHRA. The unit has
special expertise in first in man studies and is a world leader in systemic
drug phototoxicity studies in humans.
Glenn Kerkhof, Chiltern's CEO said: "We are very pleased to have
acquired DDS. This move allows us to offer leading edge Phase I services to
our global client base and supplements our existing Early Phase capability
and strong Phase II - IV capacities. The UK has long been a centre of
excellence for Early Phase clinical pharmacology and once again offers a
stable regulatory environment and internationally competitive approval
timelines. We very much look forward to building on DDS' expertise and
reputation for excellence in this sector. Chiltern also looks forward to
developing its collaboration with Ninewells Hospital and the University of
Dundee Medical School."
Dr Brian Sanderson, CEO and Medical Director of DDS, will continue to
lead the Dundee unit and will work closely with Chiltern's existing
Clinical Research Unit to build Chiltern's Early Phase service offering.
Brian comments: "Our unit in Dundee offers safe, efficient and high
quality Early Phase trials in a teaching hospital setting. The excellent
regulatory climate, with approval times of approximately 14-21 days for
Phase 1 trials, facilitates the performance of first-in-man studies in the
U.K. and our highly experienced hospital-based unit offers best practice in
this field. Not only were DDS and Chiltern established in the same year but
they also share the same core values and pedigree of excellence in clinical
trials. Thus we are delighted to be joining Chiltern today and adding our
Phase I expertise to Chiltern's existing Early Phase capacity, global reach
and strong clinical service base."
DDS will trade as Chiltern from today.
About Chiltern:
Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing
international Phase I to Phase IV clinical trials across a broad
therapeutic range for a wide variety of clients. Chiltern employs more than
1000 people with 18 offices across the United States, Europe and in India.
Chiltern provides services including Early Phase, Global Clinical
Development, Late Phase, Biometrics, Medical and Regulatory Affairs and
Resourcing Solutions.
For More Information Contact:
Catherine Lemercier Richard Baptista
Chiltern International, Inc. Chiltern International Ltd.
2111 Palomar Airport Road 171 Bath Road
Suite 200 Slough
Carlsbad Berkshire
CA 92011 SL1 4AA
USA UNITED KINGDOM
Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000
Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116
Email: Catherine.Lemercier@chiltern.com Email:
Richard.Baptista@chiltern.com
Chiltern: Understanding
SOURCE Chiltern International, Inc.
 back to top
Related links:
http://www.chiltern.com
CONTACT:
Catherine Lemercier of Chiltern
International, Inc., +1-760-707-5025, fax, +1-760-707-5022,
Catherine.Lemercier@chiltern.com; or Richard Baptista of Chiltern
International Ltd., 44 (0) 1753 512 000, fax, 44 (0) 1753 511
116, Richard.Baptista@chiltern.com
|
